Selegiline transdermal system: An examination of the potential for CYP450- dependent pharmacokinetic interactions with 3 psychotropic medications

Journal of Clinical Pharmacology

Volumn 47, Issue 2, 2007, Pages 146-158

  Azzaro, Albert J ^a   Ziemniak, John ^b   Kemper, Eva ^a   Campbell, Bryan J ^c   Vandenberg, Chad ^d  

^a Somerset Pharmaceuticals   (United States)

^b Gwynedd Pharmaceutical Consultants   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d MERCER UNIVERSITY   (United States)

Author keywords

Cytochrome P450 enzymes; Drug drug interactions; Pharmacokinetics; Selegiline; Transdermal

Indexed keywords

ALPRAZOLAM; AMPHETAMINE; ANTIDEPRESSANT AGENT; CYTOCHROME P450; DESMETHYLOLANZAPINE; DRUG METABOLITE; METHAMPHETAMINE; NORSELEGILINE; OLANZAPINE; PALIPERIDONE; PSYCHOTROPIC AGENT; RISPERIDONE; SELEGILINE; UNCLASSIFIED DRUG;

ADULT; APPLICATION SITE REACTION; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BIOEQUIVALENCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG FATALITY; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SOMNOLENCE; SYNCOPE;

ADMINISTRATION, CUTANEOUS; ADULT; ALPRAZOLAM; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MONOAMINE OXIDASE INHIBITORS; RISPERIDONE; SELEGILINE;

EID: 33846454665     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006296151     Document Type: Article

References (37)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003 ; 289: 3095-3105.
2. Goldman LS, Nielsen NH, Champion HC, for the Council on Scientific Affairs, American Medical Association. Awareness, diagnosis, and treatment of depression. J Gen Intern Med. 1999 ; 14: 569-580.
3. Preskorn SH. How drug-drug interactions can impact managed care. Am J Manag Care. 2004 ; 10 (suppl). S186 - S198.
4. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002 ; 159: 1869-1875.
5. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003 ; 64: 208-214.
6. Feiger AD, Rickels K, Rynn M, Zimbroff DL, Robinson DS. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry. 2006 ; 67: 1354-1361.
7. Amsterdam JD, Bodkin JA. Selegiline transdermal system (STS) in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group trial. J Clin Psychopharmacol. In press.
8. Barrett JS, Hochadel TJ, Morales RJ, et al. Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. Am J Ther. 1996 ; 3: 688-698.
9. Gordon MN, Muller CD, Sherman KA, Morgan DG, Azzaro AJ, Wecker L. Oral versus transdermal selegiline: antidepressant-like activity in rats. Pharmacol Biochem Behav. 1999 ; 63: 501-506.
10. Mawhinney M, Cole D, Azzaro AJ. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol. 2003 ; 55: 27-34.
11. Wecker L, James S, Copeland N, Pacheco MA. Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol Psychiatry. 2003 ; 54: 1099-1104.
12. Blackwell B, Marley E, Price J, Taylor D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry. 1967 ; 113: 349-365.
13. Brown C, Taniguchi G, Yip K. The monoamine oxidase inhibitor - tyramine interaction. J Clin Pharmacol. 1989 ; 29: 529-532.
14. Azzaro AJ, VanDenBerg CM, Blob LF, et al. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 hr in healthy subjects. J Clin Pharmacol. 2006 ; 46: 933-944.
15. Shin H-S. Metabolism of selegiline in humans: identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos. 1997 ; 25: 657-662.
16. Taavitsainen P, Anttila M, Nyman L, Karnani H, Salonon JS, Pelkonen O. Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes. Pharmacol Toxicol. 2000 ; 86: 215-221.
17. Hidestrand M, Oscarson M, Salonen J, et al. CYP2B6 and CYP2C19 are the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab Dispos. 2001 ; 29: 1480-1484.
18. Salonen JS, Nyman L, Boobis AR, et al. Comparative studies on the cytochrome P450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos. 2003 ; 31: 1093-1102.
19. Kamada T, Chow T, Hiroi T, et al. Metabolism of selegiline hydrochloride, a selective monoamine B-type inhibitor, in human liver microsomes. Drug Metab Pharmacokinet. 2002 ; 17: 199-206.
20. Lin LY, Kumagai Y, Hiratsuka A, et al. Cytochrome P4502D isozymes catalyze the 4-hydroxylation of methamphetamine enantiomers. Drug Metab Dispos. 1995 ; 23: 610-614.
21. Wang J-S, Devane CL. Pharmcokinetics and drug interactions of the sedative hypnotics. Psychopharmacol Bull. 2003 ; 37: 10-29.
22. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 ; 37: 177-193.
23. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol. 1999 ; 359: 147-151.
24. Eap CB, Bondolfi G, Zullino D, et al. Pharmacokinetic drug interaction potential of risperidone with cytochrome P450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test. Ther Drug Monit. 2001 ; 23: 228-231.
25. Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants - a pilot study. Clin Pharmacol Ther. 2004 ; 75: 386-393.
26. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997 ; 60: 284-295.
27. Zanger UM, Fischer J, Raimundo S, et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics. 2001 ; 11: 573-585.
28. Alfaro CL. Emerging role of drug interaction studies in drug development: the good, the bad, and the unknown. Psychopharmacol Bull. 2001 ; 35: 80-93.
29. Preskorn SH, Harvey AT. Cytochrome P450 enzymes and psychopharmacology. In: The American College of Neuropsychopharmacology. Psychopharmacology - The Fourth Generation of Progress [book online]. Available at: http://www.acnp.org/ g4/GN401000086/CH085.html. Accessed January 23, 2006.
30. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population. JAMA. 2002 ; 287: 337-344.
31. Silkey B, Preskorn SH, Golbeck A, et al. Complexity of medication use in the Veterans Affairs healthcare system: part II. Antidepressant use among younger and older outpatients. J Psychiatr Pract. 2005 ; 11: 16-26.
32. Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry. 2004 ; 65 (suppl 16). 27-32.
33. Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprazidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry. 2004 ; 65: 975-981.
34. Stafford RS, MacDonald EA, Finkelstein SN. National patterns of medication treatment for depression, 1987 to 2001. Primary care companion. J Clin Psychiatry. 2001 ; 3: 232-235.
35. Sandson NB, Armstrong SC, Cozza KL. An overview of psychotropic drug-drug interactions. Psychosomatics. 2005 ; 46: 464-494.
36. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab. 2002 ; 3: 13-37.
37. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol. 1992 ; 34: 262-265.